This would answer part of the reason for the market overlooking the current cash levels as it pertains to the PPS. When does IDIX plan to at least break-even on Tyzeka.
I was told idix pays 20% of the post marketing studies. But maybe that's not correct.
Either way, there's chatter on cafepharma that the US tyzeka sales arrangement is about to change, i.e. 20 idix reps will become nvs (or let go I suppose). Might be a major deal restructuring coming up soon to help idix with the burn rate. Obvious the $100-120M run rate isn't ideal.
Market Data 
Markets 
AI
